| Assessment Status | Rapid Review Complete |
| HTA ID | 21071 |
| Drug | Lorlatinib |
| Brand | Lorviqua® |
| Indication | As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. |
| Assessment Process | |
| Rapid review commissioned | 22/12/2021 |
| Rapid review completed | 13/01/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that lorlatinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
